Navigation Links
BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeek published an article on July 6 discussing the race by pharmaceutical and biotechnology companies to be first to bring to market an effective angiogenesis treatment for cardiovascular disease. While angiogenesis therapies are being pursued by Sanofi-Aventis, Boston Scientific, Baxter, and Genzyme, among others, the article highlights a very promising new biological therapy for advanced coronary artery disease (CAD) patients, FGF-1, from CardioVascular BioTherapeutics Inc. (CVBT).

BusinessWeek cites The Bruckner Group's (BGI) study presenting the preliminary value proposition for FGF-1 use in advanced coronary artery disease patients. According to BGI's study, FGF-1 has the potential to reduce treatment costs of advanced CAD patients by 20% over a five-year period after treatment.

Here is a link to the article: www.businessweek.com/technology/content/jul2007/tc2007075_259598.htm

"It's exciting when a breakthrough treatment appears with the potential to transform how we treat patients with a serious and costly disease like coronary artery disease," said Michael Russo, Partner, The Bruckner Group. "Typically, breakthrough treatments add cost to the healthcare system. BGI's study indicates, however, that FGF-1 could actually reduce total treatment costs, by as much as 20% over five years. We are looking forward to gathering evidence from the ongoing clinical trials to conclusively prove these points," Russo said.

According to Daniel Montano, CEO of CardioVascular BioTherapeutics, "The Bruckner Group's ongoing development of FGF-1's value proposition has been critical to FGF-1's commercial development. BGI's findings are allowing CVBT to have meaningful discussions with payers and employers. We are telling them that not only is a clinical breakthrough on the horizon that has the potential to revolutionize treatment for coronary artery
'"/>




Page: 1 2

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
3. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
4. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
5. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
9. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
10. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
11. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
Post Your Comments:
(Date:5/15/2008)...data reports in third quarter ...e-FirstCall/ -- VIA Pharmaceuticals,Inc. (Nasdaq:...evelopment of,compounds for the treatment of cardi...pleted patient enrollment in its acute coronary sy...Phase 2 trials investigating VIA-2291,the company...
(Date:5/15/2008)... of The American Society of Pediatric H...if., May 15 /- IDM Pharma, ...d the presentation of updated data,from a compassi...-PE) in,patients with lung metastases as a result ...en fatal bone tumor that typically affects,childre...
(Date:5/14/2008)...rstCall/ -- Progen,Pharmaceuticals Limited (ASX:PG...has resumed patient enrolment in the phase 1 dose-...e analogue, PG-11047 (formerly CGC-11047),for pati...development of PG-11047 - the lead clinical,compou...its acquisition of,Cellgate, Inc earlier this year...
(Date:5/14/2008)...MP, the leader in utilizing,single-use bioprocessi...t,partners, announced today that it has completed ...ices) standards for a Trius Therapeutics Phase I,c...osely with Trius on this GMP fill,project, an effo...ete,within a narrow deadline," said Leigh N. Pierc...
Breaking Medicine Technology:VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2PacificGMP Completes GMP Product Fill for Trius Therapeutics 2Wiley Blackwell renews carbon neutral commitment 12424 1Awareness of Heart Attack Signs Lags in U S 12420 1Awareness of Heart Attack Signs Lags in U S 12420 2Awareness of Heart Attack Signs Lags in U S 12420 3Atherosclerosis solution is likely many years away 12418 1Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec 31 2007 to 5 p m ET 12414 1
...d with maximally,tolerated lipid-lowering therapie... similar reductions in other atherogenic,when trea... CARLSBAD, Calif., March 26, 2007,/PRNewswire-Firs...ults from its ongoing Phase 2 clinical trial of IS...ercholesterolemia (HoFH),presented today at the o...
...-FirstCall/ --,Alfacell Corporation today announce...ential of ONCONASE (ranpirnase) for the,treatment ...y,published in Anticancer Research (2007; 27: 299-... the University of,Pennsylvania, a paper entitled ...nase, on A549 Human Lung Cancer Xenografts of Nude...
Other Medicine Technology:Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 3Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 4Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 6In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research 2In vivo Study Results Demonstrating Potential of Alfacell's,Onconase for Treatment of Non-Small Cell Lung Cancer Published in,Anticancer Research 3
(Date:5/16/2008)...e Vital Services for Frail Seniors and People With...e-USNewswire/ -- Thousands of,homecare workers acr...negger,s proposed cuts to hours of service, wages ...,s most vulnerable workers and the,people they ser... vital,services for seniors and people with disabi...
(Date:5/16/2008)... Urban Health Institute with 10,000 Sensual O Cond... Playboy Mansion Fundraiser, LOS ANGELES, May 16 ...p,and R & B artist J Kwon known best for his hit s... presenting the Urban Health Institute (UHI) with,... $50,000. The donation is,being made to promote th...
(Date:5/16/2008)...determine who would benefit most from chemo after ...HealthDay News) -- A panel of 15 genes may help de...cell lung cancer will experience a recurrence and,...new study shows. , By extension, the same gene... aggressive forms of the cancer who would be able ...
(Date:5/16/2008)...May 16 /PRNewswire-USNewswire/ -- As tropical stor...awaddy delta, survivors of,Cyclone Nargis are vuln...,survivors still need assistance, as exposure to t...ncreasingly dire situation., "The people living i...ver from this disaster and get back on their feet,...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2
... woman who sued them for ?250,000 over failure to ... gave birth to her daughter Jayde and sued the Per...intenance for the girl. However, the Perth Sheri...16 was given no guarantees that the abortion would...
...ore likely to be depressed, says a study//.Urinary...until you get to a restroom. The condition is twic..., and can happen for various medical reasons. The...nence is worse than either condition alone and doc...
...he smoking habit, even at older ages, because a re...nhances the risk of dying in middle age for both m...sk of premature death. The study, which scores ver...sive studies undertaken on this subject, that stud...
...ustria, Slovakia, Germany and Bosnia-Herzegovina h...rce// following reports of bird flu infection in t...rt Policy Order 2005 following issue of the notifi...e decision was taken at a high level meeting condu...
Other Medicine News:Health News:Pakistan Enforces Strict Bird Flu Measures, Poultry Import Banned 2
...d human blood cells provides a simple, cost effect...ation of urine prior to microscopic analysis in co...tion of urine sediment is a moderately complex tes...and quantitative values are provided for standardi...
...enience for urinalysis quality control one bottle...product for dipstick, hCG, and microscopics qualit...nine and microalbumin. Values are provided for mic... qualitative results for hCG are also included. Di...
... is ideal for most life science applications, espe...tented* PathCheck sensor technology senses the dep...alizes the absorbance value to a 1-cm pathlength. ... obtained in a conventional spectrophotometer. ,...
The Clearblue Easy Ovulation Test detects the surge of "luteinizing hormone in your urine, which usually happens 24 to 36 hours before you ovulate (release an egg). That means youll know the 2 best
Medicine Products: